Recursion Pharmaceuticals, Inc. (RXRX)
| Market Cap | 2.41B |
| Revenue (ttm) | 43.69M |
| Net Income (ttm) | -715.54M |
| Shares Out | 521.26M |
| EPS (ttm) | -1.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,565,583 |
| Open | 4.460 |
| Previous Close | 4.410 |
| Day's Range | 4.400 - 4.645 |
| 52-Week Range | 3.790 - 12.360 |
| Beta | 0.92 |
| Analysts | Buy |
| Price Target | 7.25 (+56.59%) |
| Earnings Date | Nov 5, 2025 |
About RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to trea... [Read more]
Financial Performance
In 2024, Recursion Pharmaceuticals's revenue was $58.84 million, an increase of 32.00% compared to the previous year's $44.58 million. Losses were -$463.66 million, 41.3% more than in 2023.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price target is $7.25, which is an increase of 56.59% from the latest price.
News
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?
Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Recursion Pharmaceuticals, Inc. ( RXRX) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants Christopher Gibson - Co-Founder, CEO & Director Najat Khan - Chi...
Is Recursion Pharmaceuticals a Meme Stock?
Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though.
Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating...
Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. ( RXRX) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Christopher Gibson - Co-Founder, CEO & Director Najat Khan - Chief R&D Officer, Chief C...
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and fin...
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President Co-Founder and CEO Chris Gibson to Transition to Chairman of the Bo...
3 Things Investors Need to Know About Recursion Pharmaceuticals
Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins.
Recursion to Participate in Upcoming Investor Conferences
Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in t...
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th
Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide bu...
Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks
Investors searching for the next Beyond Meat, Inc. (NYSE:BYND) — the latest poster child for explosive short squeezes — are eyeing the most shorted stocks as potential candidates for outsized rallies.
Up 25% in 1 Month, Is This Stock a Buy?
Many leading companies focused on artificial intelligence (AI) have seen their shares soar as they profit from the tailwind this market is currently experiencing. Perhaps a good way to cash in on this...
Recursion Pharmaceuticals (RXRX) CEO Sells 100,000 Shares
Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals (RXRX 15.70%), reported the sale of 100,000 shares on October 10, 2025, as disclosed in a SEC Form 4 filing. It appears that Gi...
Is Recursion Pharmaceuticals a Millionaire Maker?
Some investors closely monitor the portfolios of billionaires to get ideas. Another approach, however, is to examine the stocks held by highly successful companies.
4 Healthcare Stocks to Buy Now
Healthcare stocks have struggled since interest rates began climbing in 2022. Rising yields pulled capital away from speculative biotech and drug development, pushing valuations lower even as research...
What's Going On With Recursion Pharmaceuticals Stock On Wednesday?
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement.
Where Will Recursion Pharmaceuticals Be in 5 Years?
Recursion Pharmaceuticals (RXRX 1.84%), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at a...
The Biotech Stock That's Too Risky for Most Investors
The artificial intelligence (AI) revolution has the potential to alter just about every business operation for the better. One area where investors are extra excited about productivity improvements is...
10 Hidden-Gem AI Stocks to Buy Right Now
While Nvidia and Microsoft dominate artificial intelligence (AI) headlines, the smartest opportunities might lurk in smaller companies solving specific problems with the tech. These 10 hidden gems don...
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now
BigBear.ai (BBAI -6.00%) has taken investors on a rollercoaster ride in 2025. The good news, though, is that they're probably enjoying the ride these days.
Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT Company Participants Christopher Gibson - Co-Founder, CEO & Directo...
Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference Transcript
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Citi's Biopharma Back to School Conference September 3, 2025 2:30 PM EDT Company Participants Ben Taylor - CFO & President of Recursion UK Conference Cal...
3 AI Stocks Disrupting Trillion-Dollar Industries
The real artificial intelligence (AI) opportunity isn't hiding in the obvious names that dominate headlines. It's emerging in industries that have barely changed in decades -- and are now primed for A...
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today
Prosper Junior Bakiny has positions in Nvidia and Recursion Pharmaceuticals. The Motley Fool has positions in and recommends Nvidia.
1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sell
Many investors seek to capitalize on the rapidly growing artificial intelligence (AI) industry. One way to do that is to buy shares of the leading companies in the field, such as Nvidia.